Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Chemomab Therapeutics Ltd. - American Depositary Shares
(NQ:
CMMB
)
1.700
+0.020 (+1.19%)
Streaming Delayed Price
Updated: 10:15 AM EST, Jan 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Chemomab Therapeutics Ltd. - American Depositary Shares
< Previous
1
2
3
4
5
6
Next >
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
September 03, 2024
Via
Benzinga
Chemomab Therapeutics to Present at September 2024 Investor Conferences
August 28, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
↗
August 21, 2024
Chemomab Therapeutics just reported results for the second quarter of 2024.
Via
InvestorPlace
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 21, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
August 12, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
July 30, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
July 26, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
↗
July 25, 2024
Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver...
Via
Benzinga
Chemomab Therapeutics Announces $10 Million Private Placement
July 25, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
July 25, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
June 18, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
June 06, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
May 17, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024
↗
May 09, 2024
Chemomab Therapeutics just reported results for the first quarter of 2024.
Via
InvestorPlace
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
May 08, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
May 06, 2024
Via
Benzinga
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
May 02, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
April 24, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
April 18, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
April 02, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
March 25, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023
↗
March 07, 2024
Chemomab Therapeutics just reported results for the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
February 22, 2024
Via
Benzinga
Earnings Scheduled For March 7, 2024
↗
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
February 21, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
February 20, 2024
Via
Benzinga
What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?
↗
February 20, 2024
Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.
Via
Benzinga
Topics
Intellectual Property
Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
↗
January 18, 2024
Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
January 18, 2024
Pre-market stock movers are a hot topic this morning as we check out all of the winners and losers worth keeping tabs on for Thursday!
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
